For research use only. Not for therapeutic Use.
Filibuvir（Cat No.:I006602）is an investigational non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, a key enzyme in viral RNA replication. By binding to an allosteric site on the NS5B polymerase, it disrupts the replication process, reducing viral load and inhibiting disease progression. Filibuvir has been explored in clinical trials as part of combination antiviral therapies, particularly for HCV genotype 1 infections. Its oral bioavailability and selective mechanism make it a promising candidate in the development of direct-acting antivirals for managing chronic hepatitis C.
| Catalog Number | I006602 |
| CAS Number | 877130-28-4 |
| Synonyms | PF00868554; PF-00868554; P 00868554; PF868554; PF-868554; PF 868554; Filibuvir;(R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one |
| Molecular Formula | C29H37N5O3 |
| Purity | ≥95% |
| Target | Cell Cycle/DNA Damage |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | (2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one |
| InChI | InChI=1S/C29H37N5O3/c1-5-22-14-20(15-23(6-2)31-22)11-12-29(21-9-7-8-10-21)17-25(35)24(27(36)37-29)16-26-32-28-30-18(3)13-19(4)34(28)33-26/h13-15,21,35H,5-12,16-17H2,1-4H3/t29-/m1/s1 |
| InChIKey | SLVAPEZTBDBAPI-GDLZYMKVSA-N |
| SMILES | CCC1=CC(=CC(=N1)CC)CC[C@@]2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5 |
| Reference | </br>1:Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir. Wang H, Guo C, Chen BZ, Ji M.Antiviral Res. 2015 Jan;113:79-92. doi: 10.1016/j.antiviral.2014.11.005. Epub 2014 Nov 15. PMID: 25449363 </br>2:A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. Rodriguez-Torres M, Yoshida EM, Marcellin P, Srinivasan S, Purohit VS, Wang C, Hammond JL.Ann Hepatol. 2014 Jul-Aug;13(4):364-75. PMID: 24927607 Free Article</br>3:Determination and control of TEMPO, a potentially genotoxic free radical reagent used in the synthesis of filibuvir. Strohmeyer HE, Sluggett GW.J Pharm Biomed Anal. 2012 Mar 25;62:216-9. doi: 10.1016/j.jpba.2011.12.036. Epub 2012 Jan 8. PMID: 22269174 </br>4:Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M.Antimicrob Agents Chemother. 2012 Mar;56(3):1331-41. doi: 10.1128/AAC.05611-11. Epub 2011 Dec 27. PMID: 22203605 Free PMC Article</br>5:Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Yi G, Deval J, Fan B, Cai H, Soulard C, Ranjith-Kumar CT, Smith DB, Blatt L, Beigelman L, Kao CC.Antimicrob Agents Chemother. 2012 Feb;56(2):830-7. doi: 10.1128/AAC.05438-11. Epub 2011 Dec 5. PMID: 22143520 Free PMC Article</br>6:Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, Neelakantan S, Purohit VS, Hammond JL.Hepatology. 2011 Jul;54(1):50-9. doi: 10.1002/hep.24342. PMID: 21488067 </br>7:Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection. Beaulieu PL.IDrugs. 2010 Dec;13(12):938-48. Review. PMID: 21154154 |
